Sonoma Pharmaceuticals (SNOA)
(Delayed Data from NSDQ)
$3.02 USD
+0.01 (0.33%)
Updated Aug 6, 2025 03:59 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SNOA 3.02 +0.01(0.33%)
Will SNOA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SNOA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SNOA
Sonoma Pharmaceuticals (SNOA) Is Attractively Priced Despite Fast-paced Momentum
Fast-paced Momentum Stock Sonoma Pharmaceuticals (SNOA) Is Still Trading at a Bargain
SNOA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Fast-paced Mover Sonoma Pharmaceuticals (SNOA) Is a Great Choice for Value Investors
Despite Fast-paced Momentum, Sonoma Pharmaceuticals (SNOA) Is Still a Bargain Stock
Beat the Market Like Zacks: Starbucks, Shopify, 3M in Focus
Other News for SNOA
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2025 Financial Results | SNOA ...
Sonoma Pharmaceuticals GAAP EPS of -$0.48, revenue of $3.75M